Compared to wild type CAR-T cells, the granulocyte macrophage colony-stimulating factor (GM-CSF) depleted CAR-T cells by CRISPR/Cas9 produced less GM-CSF and resulted in better anti-tumor activity in vivo (74). Here, CSF2 is linked to neoplasm.